Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 3 Interventional Results available

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

ClinicalTrials.gov ID: NCT03654729

Public ClinicalTrials.gov record NCT03654729. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 5, 2026, 2:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-blind, Multicenter, Placebo-controlled Study of PledOx Used on Top of Modified FOLFOX6 (5-FU/FA and Oxaliplatin) to Prevent Chemotherapy Induced Peripheral Neuropathy (CIPN) in Patients With First-line mCRC

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study evaluates the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin.

Study identification

NCT ID
NCT03654729
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 3
Lead sponsor
Egetis Therapeutics
Industry
Enrollment
291 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 6, 2018
Primary completion
Aug 30, 2020
Completion
Aug 30, 2020
Last update posted
Dec 16, 2021

2018 – 2020

United States locations

U.S. sites
11
U.S. states
9
U.S. cities
11
Facility City State ZIP Site status
California Cancer Associates Fresno California 93720
Mid Florida Hematology and Oncology Center Orange City Florida 32763
Cancer Center of Kansas Wichita Kansas 67214
Willis-Knighton Cancer Center Shreveport Louisiana 71103
Mercy Clinic - Cancer & Hematology Springfield Missouri 65804
Mercy Clinic Oncology and Hematology St Louis Missouri 63141
CHI St Francis Cancer Treatment Center Grand Island Nebraska 68803
Hunterdon Hematology Oncology Flemington New Jersey 08822
Monter Cancer Center Lake Success New York 11042
Montefiore Medical Research The Bronx New York 10461
Scott & White Vasicek Cancer Treatment Center Temple Texas 76508

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 87 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03654729, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2021 · Synced Sep 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03654729 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →